Sotagliflozin significantly reducedthe probability of re-admission due to HF and all-cause death in HF patients.Larger-scale prospective studies are required to assess whether sotagliflozin ismore effective than other SGLT-2 inhibitors. Here, SLC5A2 is linked to hydrops fetalis.